Skip to Content
Morningstar

Jazz Pharmaceuticals PLC JAZZ

Morningstar Rating
Unlock
Stock XNAS Rating as of
$110.87 −0.36 (0.32%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Jazz Pharmaceuticals Earnings: Xywav, Rylaze, and Epidiolex Drive Sales; Shares Undervalued

Rachel Elfman

Jazz Pharmaceuticals delivered solid first-quarter results, highlighted by a 12% increase in revenue from its combined key growth drivers of Xywav, Epidiolex, and Rylaze. These fast-growing drugs helped offset a 64% decrease in Xyrem sales, as total revenue increased only 1% in the first quarter compared with the prior-year period. Jazz's results are tracking our expectations, and we maintain our fair value estimate of $187 per share. We believe shares are trading at an attractive entry point in 4-star territory about 42% below our fair value estimate. We forecast Xywav, Rylaze, and Epidiolex will continue to deliver double-digit-percentage growth in 2024, and we anticipate Jazz will reach over $4.1 billion in total revenue.

Read Full Report

Price vs Fair Value

View History
JAZZ is trading within a range we consider fairly valued.
Price
$111.21
Fair Value
$612.00
Uncertainty
High
1-Star Price
$177.87
5-Star Price
$915.70
Economic Moat
Wqsfb
Capital Allocation
Qlltdnhgf

Bulls Say, Bears Say

Bulls

The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age.

Bears

Jazz has been reliant on Xyrem, which contributed 15% of 2023 sales. Generics entered the market in January 2023 and are eroding Jazz's patient share.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if JAZZ is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$111.23
Day Range
$110.08–112.46
52-Week Range
$103.04–146.47
Bid/Ask
$110.54 / $110.89
Market Cap
$6.99 Bil
Volume/Avg
572,360 / 634,656

Key Statistics

Price/Earnings (Normalized)
6.52
Price/Sales
2.00
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
3.85%

Company Profile

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
2,800
Website
https://www.jazzpharmaceuticals.com

Competitors

Valuation

View More
Metric
JAZZ
EXEL
UCB
Price/Earnings (Normalized)
 6.5222.2625.78
Price/Book Value
 1.903.072.54
Price/Sales
 2.003.794.46
Price/Cash Flow
 6.3920.4525.55
Price/Earnings
JAZZ
EXEL
UCB

Financial Strength

Metric
JAZZ
EXEL
UCB
Quick Ratio
 1.623.230.84
Current Ratio
 2.273.461.32
Interest Coverage
 1.86—3.88
Quick Ratio
JAZZ
EXEL
UCB

Profitability

Metric
JAZZ
EXEL
UCB
Return on Assets (Normalized)
 11.13%9.61%5.10%
Return on Equity (Normalized)
 35.21%12.20%8.82%
Return on Invested Capital (Normalized)
 16.02%8.59%7.41%
Return on Assets
JAZZ
EXEL
UCB
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWrddvjbwzHdrnm$567.6 Bil
REGN
Regeneron Pharmaceuticals IncYprwvgfvtSlbpkb$106.9 Bil
VRTX
Vertex Pharmaceuticals IncVryrnpnpQqqfmvm$105.9 Bil
MRNA
Moderna IncTwjnnmlwcJbcqr$46.4 Bil
ARGX
argenx SE ADRVhvrnnsyDpj$23.5 Bil
BNTX
BioNTech SE ADRNwvvmfscSclh$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncGttnzcbBztkkj$19.5 Bil
BMRN
Biomarin Pharmaceutical IncQptvqzkydVdpxsbt$15.7 Bil
RPRX
Royalty Pharma PLC Class AYbyyzvxzXjhhnnr$12.8 Bil
INCY
Incyte CorpSmwxqmpkFrxmnq$12.2 Bil

Sponsor Center